The EMA is reviewing some slimming medication for suicide-related dangers – Muricas News

EMA’s security committee, the Prac, is inspecting information on the danger of suicidal ideas and ideas of self-harm with medicines often called Glp-1 receptor agonists, together with Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). These are medication used for weight reduction and for the therapy of kind 2 diabetes.

The overview was initiated by the Icelandic medicines company following reviews of suicidal ideas and self-harm in folks utilizing liraglutide and semaglutide-based medicines. Up to now, authorities have recovered and are analyzing round 150 reviews of potential circumstances of self-harm and suicidal ideas.

“The medication liraglutide and semaglutide are extensively used, with an publicity of greater than 20 million patient-years up to now. It's nonetheless unclear whether or not the reported circumstances are associated to the medication themselves or to the sufferers’ underlying circumstances or different components. “, explains the EMA.

“The overview is ongoing as a part of a reporting course of. A sign is details about a brand new hostile occasion doubtlessly brought on by a medicinal product or a brand new side of a identified hostile occasion that requires additional investigation. The presence of a sign it doesn’t essentially imply that a medication triggered the hostile occasion in query,” he factors out.

The overview of Ozempic, Saxenda and Wegovy started on July 3 and has now been expanded to incorporate different Glp-1 receptor agonists. The overview is anticipated to conclude in November 2023.